AU3711900A - Method of increasing bone volume using non-naturally-occurring ep1 selective agonists - Google Patents

Method of increasing bone volume using non-naturally-occurring ep1 selective agonists Download PDF

Info

Publication number
AU3711900A
AU3711900A AU37119/00A AU3711900A AU3711900A AU 3711900 A AU3711900 A AU 3711900A AU 37119/00 A AU37119/00 A AU 37119/00A AU 3711900 A AU3711900 A AU 3711900A AU 3711900 A AU3711900 A AU 3711900A
Authority
AU
Australia
Prior art keywords
naturally
occurring
agonist
bone
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37119/00A
Other languages
English (en)
Inventor
Mitchell Anthony Delong
James Richard Hartke
Mark Walden Lundy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of AU3711900A publication Critical patent/AU3711900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU37119/00A 1999-03-05 2000-03-01 Method of increasing bone volume using non-naturally-occurring ep1 selective agonists Abandoned AU3711900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12306399P 1999-03-05 1999-03-05
US60123063 1999-03-05
PCT/US2000/005196 WO2000051585A2 (fr) 1999-03-05 2000-03-01 Augmentation du volume osseux par utilisation d'agonistes selectifs d'ep1 n'existant pas naturellement

Publications (1)

Publication Number Publication Date
AU3711900A true AU3711900A (en) 2000-09-21

Family

ID=22406507

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37119/00A Abandoned AU3711900A (en) 1999-03-05 2000-03-01 Method of increasing bone volume using non-naturally-occurring ep1 selective agonists

Country Status (10)

Country Link
EP (1) EP1158969A2 (fr)
JP (1) JP2002538105A (fr)
AU (1) AU3711900A (fr)
CA (1) CA2366755A1 (fr)
CO (1) CO5150205A1 (fr)
IL (1) IL145128A0 (fr)
NO (1) NO20014192L (fr)
NZ (1) NZ513828A (fr)
PE (1) PE20001552A1 (fr)
WO (1) WO2000051585A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1878429B1 (fr) 2005-04-28 2011-08-03 Ono Pharmaceutical Co., Ltd. Préparation pour absorption transdermale
KR20090075864A (ko) 2006-10-26 2009-07-09 오노 야꾸힝 고교 가부시키가이샤 첨부제
EP2305304A4 (fr) 2008-04-28 2011-08-10 Nat University Corp Hamamatsu University School Of Medicine Immunostimulant comprenant l' agoniste ep1
CA2792161A1 (fr) * 2010-03-05 2011-09-09 University Of Rochester Inhibition d'ep1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3982016A (en) * 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
WO1992021350A1 (fr) * 1991-05-29 1992-12-10 Sepracor, Inc. Combinaison de medicaments anti-inflammatoires non steroidiens et de prostaglandines et leur utilisation
KR20010023840A (ko) * 1997-09-09 2001-03-26 데이비드 엠 모이어 비천연 선택성 ｆｐ 아고니스트를 이용한 골 부피 증가 방법
EP1121133A1 (fr) * 1998-10-15 2001-08-08 Merck & Co., Inc. Methodes de stimulation de la formation osseuse
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives

Also Published As

Publication number Publication date
PE20001552A1 (es) 2001-01-30
CO5150205A1 (es) 2002-04-29
JP2002538105A (ja) 2002-11-12
WO2000051585A2 (fr) 2000-09-08
WO2000051585A3 (fr) 2001-01-25
CA2366755A1 (fr) 2000-09-08
NZ513828A (en) 2001-09-28
EP1158969A2 (fr) 2001-12-05
IL145128A0 (en) 2002-06-30
NO20014192D0 (no) 2001-08-29
NO20014192L (no) 2001-11-05

Similar Documents

Publication Publication Date Title
US6156799A (en) Method of increasing bone volume using non-naturally-occurring FP selective agonists
EP0741567B1 (fr) Inhibition de la migration et la proliferation des cellules musculaires lisses a l'aide de composes d'hydroxycarbazole
CA1327003C (fr) Usage pharmacologique de l'uridine dans le traitement de troubles nerveux
TWI302100B (en) Composition for treating drug-induced constipation
US20020187169A1 (en) Kavalactone compositions
JPWO2003007991A1 (ja) Ｌｐａ受容体調節剤からなる膵液分泌制御剤
EP1140054B1 (fr) Nouvelles compositions et trousses de bretylium, et leur utilisation dans la prevention et le traitement des pathologies cardio-vasculaires
AU3711900A (en) Method of increasing bone volume using non-naturally-occurring ep1 selective agonists
US20030158247A1 (en) Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
AU9130298A (en) Method of increasing bone volume
WO2000051616A1 (fr) Procede d'accroissement du volume osseux a l'aide de derives de prostaglandine agonisant de maniere selective fp et ep1, non naturels
WO2003070252A1 (fr) Agents antiprurigineux
MXPA00002395A (en) Method of increasing bone volume
JP5039236B1 (ja) 抗不整脈剤及び心房細動抑制剤
MXPA00002394A (en) Method of increasing bone volume using non-naturally-occurring fp selective agonists
JPH1135470A (ja) ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
CZ2000808A3 (cs) Použití selektivního FP agonisty, který se přirozeně nevyskytuje
JP2002538122A (ja) 天然に存在しないｆｐ選択的アゴニストおよび骨吸収抑制化合物を用いる骨体積の増加方法
JP5615868B2 (ja) 持続性心房細動モデル及びその製造方法、並びに、心房細動抑制剤のスクリーニング方法
FR2648043A1 (fr) Utilisation de phenylethanolamines pour la preparation de medicaments pour les affections oculaires

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted